Hurler Syndrome Clinical Trial
Official title:
MT2011-21C Laronidase (Aldurazyme TM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH).
This is a standard of care treatment guideline for patients with the diagnosis of mucopolysaccharidosis type IH (MPS I, Hurler syndrome) who are being considered as candidates for first hematopoietic stem cell transplantation (HSCT) according to a University of Minnesota myeloablative HSCT protocol.
Laronidase Enzyme Replacement Therapy will be performed using laronidase once a week for 12 weeks prior to hematopoietic stem cell transplantation and for 8 weeks post-transplant to reduce pulmonary complications. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00146757 -
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old
|
Phase 2 | |
Completed |
NCT01173016 -
Administration of IV Laronidase Post Bone Marrow Transplant in Hurler
|
Phase 1 | |
Completed |
NCT00176891 -
Stem Cell Transplant w/Laronidase for Hurler
|
Phase 2 | |
Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02171104 -
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
|
Phase 2 | |
Completed |
NCT01917708 -
Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
|
Phase 1 | |
Completed |
NCT00638547 -
Intrathecal Enzyme Replacement for Hurler Syndrome
|
Phase 1 | |
Withdrawn |
NCT00286689 -
Effects of Growth Hormone in Chronically Ill Children
|
N/A | |
Completed |
NCT01873911 -
Neurobehavioral Phenotypes in MPS III
|
||
Completed |
NCT01043640 -
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
|
Phase 2 | |
Completed |
NCT00258011 -
Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease
|
Phase 3 | |
Active, not recruiting |
NCT03580083 -
RGX-111 Gene Therapy in Patients With MPS I
|
Phase 1/Phase 2 | |
No longer available |
NCT03639844 -
BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study
|